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Introduction {#sec001}
============

Cisplatin (*cis*-diamminedichloroplatinum II; CDDP) is widely used as a chemotherapeutic agent for a variety of cancers. However, one-third of patients treated with CDDP develop nephrotoxicity, which limits the application of this drug \[[@pone.0235849.ref001], [@pone.0235849.ref002]\]. CDDP-induced nephrotoxicity is associated with damage to the S1 and S3 segments of the proximal tubules. Moreover, high concentrations of CDDP induce necrosis of the kidney tissues, whereas lower concentrations can promote apoptosis in human kidney cells \[[@pone.0235849.ref003]\].

CDDP causes reactive oxygen species (ROS)-induced oxidative stress and lipid peroxidation, which result in membrane dysfunction and production of toxic metabolites. A relationship between tumor necrosis factor-α (TNF-α) and CDDP-induced nephrotoxicity was previously described \[[@pone.0235849.ref004]--[@pone.0235849.ref007]\].

Cisplatin-induced nephrotoxicity is mediated by oxidative stress \[[@pone.0235849.ref001], [@pone.0235849.ref002], [@pone.0235849.ref008]\]. The balance between ROS and antioxidant enzymes affects the degree of organ damage \[[@pone.0235849.ref009]\]. Methylglyoxal (MG), also known as 2-oxopropanal or pyruvaldehyde, contains two carbonyl groups and reacts with proteins and nucleic acids to generate MG-adducts. These advanced glycation end products can lead to protein denaturation and malfunctions that induce mitochondrial dysfunction and cellular apoptosis \[[@pone.0235849.ref010]--[@pone.0235849.ref013]\]. The levels of MG and its metabolite D-lactate correlate with oxidative stress in animal models of severe kidney injury \[[@pone.0235849.ref014]--[@pone.0235849.ref023]\]. However, the precise involvement of MG and D-lactate in CDDP-induced nephrotoxicity are unclear.

Proteomics, the study of proteins in biological specimens and the interactions between proteins and pathological conditions \[[@pone.0235849.ref024]--[@pone.0235849.ref026]\], has provided significant insight into various mechanisms of disease \[[@pone.0235849.ref027]\]. Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) is widely applied in proteomic studies, but is a complicated technique with low sensitivity and reproducibility \[[@pone.0235849.ref028]\]. Fluorogenic derivatization-liquid chromatography-tandem mass spectrometry (FD-LC-MS/MS) can successfully identify proteins in biological samples. A series of studies applied FD-LC-MS/MS to screen unknown proteins and identify their roles under physiological and pathological conditions in animal tissue and human cell lines \[[@pone.0235849.ref026], [@pone.0235849.ref029], [@pone.0235849.ref030]\].

In this study, we aimed to confirm whether MG and D-lactate play a role in CDDP-induced kidney injury. Specifically, a FD-LC-MS/MS proteomic method was employed to explore the proteins involved in a mouse model of oxidative stress-related acute kidney injury (AKI) induced by CDDP.

Materials and methods {#sec002}
=====================

Chemicals {#sec003}
---------

Bovine serum albumin (BSA), 4-methylumbelliferyl *N*-acetyl-β-D-glucosaminide (4-MU-NAG), 4-methylumbelliferone (4-MU), the periodic acid-Schiff (PAS) kit, citric acid, ammonium chloride (NH~4~Cl), propionic acid, tris(2-carboxethyl)phosphine hydrochloride (TCEP), guanidine buffer, calcium chloride (CaCl~2~), ammonium bicarbonate (NH~4~HCO~3~), sodium dodecyl sulfate (SDS) and 30% acrylamide were purchased from Sigma Chemical Co. Ltd (St Louis, MO, USA); 5,6-diamino-2,4-hydroxypyrimidine sulfate (DDP), 4-nitro-7-piperazino-2,1,3-benzoxadiazole (NBD-PZ), 2,2-dipyridyl disulfate (DPDS), triphenyl phosphine (TPP) and 7-chloro-N-\[2-(dimethylamino) ethyl\]-2,1,3-benzoxadiazole-4-sulfonamide (DAABD-Cl) were purchased from Tokyo Kasei Chemicals (Tokyo, Japan); 3-\[(3-cholamidopropyl) dimethylammonio\] propanesulfonic acid (CHAPS), trifluoroacetic acid (TFA) and ethylenediaminetetraacetic acid disodium salt (EDTA•2Na) were purchased from Wako Pure Chemicals Industries Ltd (Tokyo, Japan). HPLC-grade acetonitrile (ACN), methanol (MeOH) and MS-grade formic acid (FA) were obtained from Merck (Darmstadt, Germany).

Derivatives were separated and collected using high-performance liquid chromatography with a fluorescence detector (FD-HPLC; Hitachi, Tokyo, Japan). After digesting the isolated derivatives, the samples were identified by LC-MS/MS (4000 QTRAP; Applied Biosystems, Foster City, CA, USA) with the MASCOT database searching system. Trypsin was purchased from Promega (Fitchburg, WI, USA).

Animal model of CDDP-induced AKI {#sec004}
--------------------------------

All animal protocols followed the ethical guidelines of the Institutional Animal Care and Use Committee of Taipei Medical University (LAC-2019-0167). Twenty-five six-week-old female BALB/c mice were purchased from the National Laboratory Animal Center Foundation and randomly allocated to three groups, control, CDDP administration for 3 days (CDDP 3 days) and CDDP administration for 5 days (CDDP 5 days). Five animals were allocated into one group. All animals were allowed to acclimatize to the environment for a week before the experiments started. All animals had free access to water and food and were housed at 21 °C and 70--80% relative humidity under a normal feeding environment.

To induce acute kidney injury (AKI), the mice were injected with CDDP (5 mg/kg/day) intraperitoneally for 3 or 5 days. Mice were humanely sacrificed on day 4 or day 6 and the kidneys were dissected and stored at -80 °C directly for further analysis \[[@pone.0235849.ref014], [@pone.0235849.ref026]\]. Blood samples were obtained when the mice were sacrificed. Animals were sacrificed under isoflurane anesthesia, and all efforts were made to minimize suffering.

Biochemical assays {#sec005}
------------------

A specialized metabolism device (Tokiwa Precious Metals, Japan) was used to collect 12-hour urine samples on day 3 and day 5 \[[@pone.0235849.ref014], [@pone.0235849.ref026]\].

Renal function was evaluated by assessing blood urea nitrogen (BUN), *N*-acetyl-β-D-glucosaminide (NAG) and urinary creatinine. BUN and urinary creatinine were determined using a dimension clinical chemistry system (Dade Behring Inc., Deerfield, IL, USA).

NAG activity was measured using a fluorometric assay to detect 4-MU \[[@pone.0235849.ref014], [@pone.0235849.ref026]\]. In brief, 4-MU-NAG was reacted with NAG in the urinary samples in 100 mM citrate buffer (pH 4.6--5.0) at 37 °C. The reaction was terminated after 15 min by the addition of 200 mM glycine buffer (pH 10.4--10.6), and the fluorescence intensity of 4-MU was quantified at excitation/emission wavelengths of 370/460 nm.

Histopathologic analysis {#sec006}
------------------------

Approximately half of the left kidney of each mouse was stained with periodic acid--Schiff (PAS) reagent following a previously published method \[[@pone.0235849.ref031]\]. Sections were observed at 200× using a light microscope.

The degree of kidney injury was assessed using the tubulointerstitial histological score (TIHS), which assesses degeneration of the tubular epithelium (scored from 0--5), mononuclear cell infiltration into the interstitium (scored from 0--3), and interstitial fibrosis (scored from 0--5). A higher TIHS score represents more severe damage \[[@pone.0235849.ref026], [@pone.0235849.ref031], [@pone.0235849.ref032]\].

Immunofluorescence assay {#sec007}
------------------------

Approximately half of the left kidney of each mouse was subjected to immunofluorescence analysis. Frozen kidney sections were rinsed in phosphate buffered saline (PBS) at room temperature, blocked in 10% control rabbit serum and incubated with TNF-α primary antibody (1:200); sc-52746; Santa Cruz Inc., Dallas, TX, USA). TRITC-labeled IgG (Santa Cruz Inc., USA) was used as a secondary antibody, then the samples were washed three times in PBS, mounted and the fluorescent signals were detected using an Olympus Fluoview FV500 Laser Scanning Confocal System (Tokyo, Japan).

Preparation of homogenized kidney samples {#sec008}
-----------------------------------------

Approximately 500 mg of tissue from the right kidney was homogenized in 500 μL of PBS using a Precellys 24 Tissue Homogenizer (Brevet Bertin Technologies, Montignyle, France) at 6000 rpm for 30 sec, centrifuged at 8000 rpm for 20 min at 4 °C, the supernatant was collected and the total protein content was quantified using the Pierce^™^ BCA Protein Assay Kit (Thermo Fisher Scientific Inc, Waltham, MA, USA) using BSA as a protein standard.

Analysis of MG in homogenized kidney samples {#sec009}
--------------------------------------------

The kidney MG content was determined by FD-HPLC according to previously published methods \[[@pone.0235849.ref014], [@pone.0235849.ref021], [@pone.0235849.ref033]\]. Briefly, 20 μL homogenized kidney samples were incubated with DDP at 60 °C for 30 min in 0.5 M ammonium chloride buffer (pH 10.0). The reaction was stopped by addition of 0.01 M citric acid (pH 6.0). Samples (20 μL) were injected onto the HPLC and separated using an ODS column (150 × 4.6 mm, 5 μm particle size; Biosil Chemical Co. Ltd., Taipei, Taiwan). The mobile phase was 97:3 (*v/v*) 0.01 M citric acid buffer (pH 6.0)/ACN and the flow rate was 0.7 mL/min. The temperature was fixed at 33 °C. The detector was set to excitation/emission wavelengths of 330/500 nm. Quantification was performed by integrating the height of the corresponding peaks on the chromatograms using a D-7500 integrator (Hitachi) and adjusting to the protein concentration of the tissue sample.

Analysis of D-lactate in homogenized kidney samples {#sec010}
---------------------------------------------------

A two-dimensional column-switching FD-HPLC system was used to determine kidney D-lactate content \[[@pone.0235849.ref022], [@pone.0235849.ref032]\]. Homogenized kidney samples (20 μL) were mixed with 10 μL of propionic acid (as an internal standard) and 170 μL ACN and centrifuged at 700 *g* for 10 min at 4 °C to precipitate protein. Then, 100 μL of the supernatant was derivatized by adding 100 μL of 8 mM NBD-PZ, 25 μL of 280 mM DPDS and 25 μL of 280 mM TPP. The reactions were incubated at 30 °C for 3 h and stopped by addition of 250 μL of 0.1% TFA ~(*a*.*q*.)~. The samples were purified using MonoSpin^™^ SCX cartridges (GL Science Inc., Tokyo, Japan) to remove excess derivatizing agent.

The lactate derivatives were first separated on an Aqu-ODS-W-5u column (250 × 4.6 mm, 5 μm particle size; Biosil Chemical Co. Ltd, Taipei, Taiwan) using 68:12:20 (*v/v/v*) H~2~O/ACN/MeOH as the mobile phase at 30 °C. The flow rate was 0.7 mL/min for 0--35 min and 0.9 mL/min for 35.1--60 min. The fraction containing the lactate derivatives was collected and injected onto a Chiralpak AD-RH column (150 × 4.6 mm, 5 μm particle size; Daicel Co. Osaka, Japan) to separate D-lactate and L-lactate. The mobile phase was 40:60 (*v/v*) H~2~O/ACN at a flow rate of 0.3 mL/min. The detector for detecting the fraction containing lactate derivatives was set to excitation/emission wavelengths of 330/500 nm. The detectors for detecting D/L-lactate derivatives was set to excitation/emission wavelengths of 491/547 nm. Quantification was performed by integrating the areas of the corresponding peaks on the chromatograms (D-7500 integrator; Hitachi) and adjusting to the protein concentration of each sample.

Sample preparation and protein derivatization {#sec011}
---------------------------------------------

Approximately 500 mg of tissue from the kidney was homogenized in 2000 μL of 10 mM CHARS using a Precellys 24 Tissue Homogenizer (Brevet Bertin Technologies, Montignyle, France) at 6000 rpm for 30 sec, centrifuged at 8000 rpm for 20 min at 4 °C. The supernatant was collected and the total protein content was quantified by using the pervious method. Tissue homogenates were diluted into 4.0 mg/mL protein by 10 mM CHAPS. 20 μL of 50 mM CHAPS, 20 μL of 2.5 mM TCEP, 20 μL of 10 mM EDTA∙2Na, 25 μL of 8 M guanidine and 5 μL of 140 mM DAABD-Cl were added to 10 μL of the diluted samples. The reactions were incubated at 40 °C for 10 min and stopped by adding 20% TFA.

FD-HPLC proteomic analysis {#sec012}
--------------------------

The FD-HPLC conditions were modified from a previous method \[[@pone.0235849.ref024]--[@pone.0235849.ref026]\]. The system was composed of a Hitachi HPLC system and L-2485 fluorescence detector at excitation/emission wavelengths of 395/505 nm. Derivatized protein samples (40 μL) were injected into the HPLC system at a flow rate of 0.55 mL/min. Mobile phase A was 9:1:90:0.15 (*v/v/v/v*) ACN/isopropanol/H~2~O/TFA, mobile phase B was 69:1:30:0.15 ACN/isopropanol/H~2~O/TFA (*v/v/v/v*) and mobile phase C was 4:1:95:0.20 (*v/v/v/v*) ACN/isopropanol/H~2~O/TFA. The gradient elution program is shown in [Table 1](#pone.0235849.t001){ref-type="table"}. A reverse-phase column (Intrada WP-RP, 250 x 4.6 mm i.d., Imtakt Co., Kyoto, Japan) was used to separate proteins at 60 °C based on polarity. The peaks obtained from the control and CDDP-treated mouse kidney samples were compared and the differential peaks were isolated and identified using LC-MS/MS and the MASCOT database \[[@pone.0235849.ref024]--[@pone.0235849.ref026]\].

10.1371/journal.pone.0235849.t001

###### Gradient elution program for FD-HPLC proteomic analysis.

![](pone.0235849.t001){#pone.0235849.t001g}

  Phase   Time (min)                                                                    
  ------- ------------ ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- -----
  A (%)   94           94   35   30   27   1    1    0    0    0    0    0    0    0    0
  B (%)   5            5    30   30   38   44   44   47   48   51   60   70   90   90   100
  C (%)   1            1    35   35   35   55   55   53   52   49   40   30   10   10   0

Protein identification {#sec013}
----------------------

The organic mobile phase was evaporated using a Savant Speed Vac (Model SPD111V; Thermo Fisher Scientific Inc, Waltham, MA, USA). Then, 2.5 μL of 10 mM CaCl~2~, 20 μL of 50 mM NH~4~CO~3~ and 2.5 μL trypsin were added to the protein residues and incubated at 37 °C for 2 h. The samples were loaded onto a nanopore-column (Zorbax 300SB-C18; 5 x 0.3 mm I.D.; Agilent, Santa Clara, CA, USA) and eluted using 0.10% TFA in 2.0% ACN at a flow rate of 10 μL/min. The mixtures were then separated on a C~18~ nanoflow column (75 μm i.d. x 150 cm, C18 NanoEase, particle size 3.5 μm) at a flow rate of 0.5 μL/min. Mobile phase D was 2:98:0.1 (*v/v/v*) ACN/H~2~O/FA and mobile phase E was 98:2:0.1 (*v/v/v*) ACN/H~2~O/FA. The gradient elution program is shown in [Table 2](#pone.0235849.t002){ref-type="table"}.

10.1371/journal.pone.0235849.t002

###### Gradient elution program for LC-MS/MS for proteomic analysis.

![](pone.0235849.t002){#pone.0235849.t002g}

  Phase   Time (min)                       
  ------- ------------ ---- ---- ---- ---- ----
  D (%)   95           95   60   20   20   95
  E (%)   5            5    40   80   80   5

Peptide samples were injected into a API 4000 QTRAP MASS spectrometer (Agilent, Santa Clara, CA, USA) via a distal coated fused-silica needle (75 μm tube i.d., 15 μm tip i.d.; PicoTip^™^ Emitter, New Objective, MA, USA). One-second MS/MS scans were conducted for each precursor ion. Ions with a *m/z* ratio between 350 and 1250 were fragmented using capillary energies ranging from 1300--2500 V; the temperature of the interface heater was 150 °C.

After detection, data was submitted to MASCOT, a protein identification program, which is one of the LC-MS/MS protein identification system by Matrix Science Ltd. ([www.matrixscience.com/](http://www.matrixscience.com/)). MASCOT is widely-used protein identification search engine. The proteins were identified using MASCOT version 2.2, NCBInr as the database, 0.5 Da as peptide tolerance and MS/MS tolerance, 2+ for the peptide charge. As previous research described \[[@pone.0235849.ref025]--[@pone.0235849.ref027], [@pone.0235849.ref030], [@pone.0235849.ref031]\].

Western blotting {#sec014}
----------------

Homogenized kidney samples (15 μg per lane) were separated on 12% SDS/polyacrylamide gels and electrophoretically transferred onto PVDF membranes. The membranes were incubated with primary antibodies against mice parkinson disease protein 7 (DJ-1; 1:5000 dilution; GTX132552, GeneTex, CA, USA), superoxide dismutase 1 (SOD1; 1:3000 dilution; 100554; GeneTex) and β-actin (rabbit polyclonal beta actin antibody (1:2000 dilution; 20536--1-AP; Proteintech, Rosemont, IL, USA) as an internal control. HRP-conjugated Affinipure Goat Anti-Mouse IgG (H+L) (1:4000; SA00001--1; Proteintech) was used as the secondary antibody. The signals were determined using the enhanced chemiluminescence kit (BIOTOOLS, New Taipei City, Taiwan). The relative levels of DJ-1 and SOD-1 were assessed semi-quantitatively, normalized to β-actin and expressed relative to the respective controls using Image J (National Institute of Mental Health, Bethesda, MD, USA).

Results {#sec015}
=======

Biochemical analysis of CDDP-induced AKI {#sec016}
----------------------------------------

The biochemical analysis is summarized in [Fig 1](#pone.0235849.g001){ref-type="fig"} Compared to control mice at the same time points, urinary creatinine was significantly lower (*p* \<0.05) at days 3 and 5 in the mice injected with CDDP. Moreover, BUN was significantly higher at day 5 (but not day 3) and NAG was significantly higher at days 3 and 5 in the CDDP group compared to the control group. These biochemical data indicate that administration of CDDP for 3 and 5 days damaged the kidney function of the mice.

![Biochemical analysis of CDDP-induced AKI.\
(A) Urinary creatinine, (B) NAG activity and (C) BUN in the control group, CDDP 3-day group and CDDP 5-day group. NAG: *N*-acetyl-acetylglucosaminidase, BUN: blood urea nitrogen, \*p \< 0.05, Student's T-test. N = 5 in each group, every experiment was conducted in triplicate.](pone.0235849.g001){#pone.0235849.g001}

PAS staining and confocal imaging {#sec017}
---------------------------------

Compared to the control group, the mice administered CDDP for 3 and 5 days exhibited damage to the renal tubules, including tubular cell atrophy and cell infiltration. The TIHS of the PAS-stained tissues confirmed that CDDP-induced pathological changes were observed in both the CDDP 3-day group and CDDP 5-day group. The damage was more severe in the CDDP 5-day group than the CDDP 3-day group ([Fig 2](#pone.0235849.g002){ref-type="fig"}).

![Periodic acid Schiff (PAS)-stained kidney tissues.\
(A) control group (B) CDDP 3-day group and (C) CDDP 5-day group (x200). Both the CDDP 3-day group and CDDP 5-day group exhibited renal tubule damage, such as tubular cell atrophy and cell infiltration. (D) Tubulointerstitial histological scores (TIHS) of the PAS-stained tissues; \*\*p \< 0.01 vs. control group, Student's T-test. N = 5 in each group, every experiment was conducted in triplicate.](pone.0235849.g002){#pone.0235849.g002}

Confocal microscope images of immunofluorescently stained kidney sections are shown in [Fig 3](#pone.0235849.g003){ref-type="fig"}. TNF-α was expressed at low levels in the control group and the highest levels in the CDDP 5-day group. Overall the results if biochemical, histological and Immunofluorescence assay indicated that CDDP induced kidney damage.

![Confocal microscopy of TNF-α expression in the kidney tissue.\
(A) control group (B) CDDP 3-day group (C) CDDP 5-day group (D) Semi-quantitative analysis of the levels of TNF-α based on the confocal microscopy images; \*\*p \< 0.01 vs. control group, Student's T-test. N = 5 in each group, every experiment was conducted in triplicate.](pone.0235849.g003){#pone.0235849.g003}

MG content of kidney tissues {#sec018}
----------------------------

We used reverse-phase HPLC coupled to a fluorescence detector to quantify the MG contents of the mice kidney tissues ([Fig 4](#pone.0235849.g004){ref-type="fig"}; [S1 Fig](#pone.0235849.s001){ref-type="supplementary-material"}). The MG contents were 0.019± 0.002 for the control group, 0.022 ± 0.002 for the CDDP 3-day group and 0.036 ± 0.002 μg/g protein for the CDDP 5-day group. The MG content of the CDDP 5-day group, but not the CDDP 3-day group, was significantly higher (*p* \< 0.05) than the MG content of the control group. This result confirms that administration of CDDP for 5 days significantly increased the production of MG in the kidney.

![The quantification results of methylglyoxal content in the kidney tissues.\
\*p \< 0.05 vs. control group, Student's T-test. N = 5 in each group, every experiment was conducted in triplicate.](pone.0235849.g004){#pone.0235849.g004}

D-Lactate content in kidney tissues {#sec019}
-----------------------------------

A two-dimensional column switching system with a fluorescence detector was to quantify the D-lactate contents of the kidney tissues ([Fig 5](#pone.0235849.g005){ref-type="fig"}; [S2 Fig](#pone.0235849.s002){ref-type="supplementary-material"}). The D-lactate content was 1.12 ± 0.06 in the control group, 1.39 ± 0.35 in the CDDP 3-day group and 1.78 ± 0.29 nmol/mg protein in the CDDP 5-day group. Although there was no significant difference between groups, the D-lactate content tended to increase as the MG content increased.

![Two-dimensional column-switching HPLC quantification of D-lactate in the kidney tissues.\
The content of D-lactate was increased in CDDP 3-day and CDDP 5-day group, tended to increase as the MG content increased. N = 5 in each group, every experiment was conducted in triplicate.](pone.0235849.g005){#pone.0235849.g005}

FD-LC-MS/MS proteomic analysis {#sec020}
------------------------------

The FD-LC-MS/MS chromatograms for the control, CDDP 3-day and CDDP 5-day groups are shown in [Fig 6](#pone.0235849.g006){ref-type="fig"}. The 33 and 9 peaks with significantly different peak heights in the CDDP 3-day and CDDP 5-day groups, respectively, compared to the control group were collected for LC-MS/MS analysis and identified using the MASCOT database.

![FD-HPLC chromatograms of protein separation of the mouse kidney homogenates.\
Compared to the control group (A), 33 peaks were significantly altered in the CDDP 3-day group (B) and 9 peaks were significantly altered in the CDDP 5-day group (C).](pone.0235849.g006){#pone.0235849.g006}

The proteins identified in the CDDP 5-day group were mostly unremarkable, such as hemoglobin or cytoskeletal proteins ([S2 Table](#pone.0235849.s004){ref-type="supplementary-material"}). However, 11 antioxidant-related proteins were identified in the CDDP 3-day group ([Fig 7](#pone.0235849.g007){ref-type="fig"}; [Table 3](#pone.0235849.t003){ref-type="table"}; [S1 Table](#pone.0235849.s003){ref-type="supplementary-material"}). From these 11 proteins, SOD-1 and DJ-1 were selected as target proteins and their expression levels were confirmed via western blotting.

![FD-HPLC quantification of oxidative stress-associated proteins.\
The oxidative stress-associated proteins in the kidney homogenates of the control group, CDDP 3-day group and CDDP 5-day group. The peaks were quantified based on peak height; \*p \< 0.05 vs. control group, Student's T-test.](pone.0235849.g007){#pone.0235849.g007}

10.1371/journal.pone.0235849.t003

###### The antioxidant-related proteins identified in kidney samples by FD-LC-MS/MS proteomic analysis using the MOSCOT database.

![](pone.0235849.t003){#pone.0235849.t003g}

  Retention time (min)   Proteins (Abbreviation)                    MW. (kDa)   Score   GI NO.
  ---------------------- ------------------------------------------ ----------- ------- --------------
  44.4                   Cu/Zn superoxide dismutase (SOD1)          15,752      91      gi\|226471
  178.8                  Cu/Zn superoxide dismutase (SOD1)          15,752      78      gi\|226471
  200.8                  Glutathione peroxidase (GSH-Px)            22,276      55      gi\|2673845
  200.8                  Peroxisomal membrane protein 20 (PMP20)    17,004      76      gi\|6746357
  204                    Peroxisomal membrane protein 20 (PMP20)    17,004      76      gi\|6746357
  212.5                  Peroxisomal membrane protein 20 (PMP20)    17,004      183     gi\|6746357
  215.6                  Peroxiredoxin V (PRDX 5)                   21,975      48      gi\|6644338
  215.6                  Parkinson disease protein 7 (DJ-1/PARK7)   20,008      68      gi\|55741460
  218.5                  Peroxiredoxin-6 (PRDX6)                    24,855      64      gi\|3219774
  231.2                  Catalase                                   36,564      90      gi\|10946870
  231.2                  Aldo-keto reductase family 1, member A4    46,555      83      gi\|6996911
  237.6                  Peroxiredoxin 1 (PRDX1)                    22,162      41      gi\|6754976
  231.2                  Glutathione S-transferase mu 1 (GSTM1)     3,242       51      gi\|50165

Western blotting {#sec021}
----------------

The semi-quantitative analysis of the western blots revealed DJ-1 and SOD-1 were expressed at 1.9-fold (*p* \< 0.05) and 1.25-fold (*p* \< 0.05) higher levels in the kidney tissue homogenates of the CDDP 3-day group than the control group ([Fig 8](#pone.0235849.g008){ref-type="fig"}). DJ-1 and SOD-1 also tended to be expressed at higher levels in the CDDP 5-day group than the control group, though the differences were not significant. These results were consistent with the FD-LC MS-MS proteomics study and confirmed that DJ-1 and SOD-1 were upregulated in the kidney after treatment with CDDP for 3 days.

![Expression of DJ-1 and SOD1 in the kidney homogenate.\
(A) Representative western blots of DJ-1, SOD-1 and β-actin expression. β-actin was used as the internal standard. (B-C) Quantification of DJ-1 and SOD-1 protein expression. SOD1: Cu-Zn superoxide dismutase; DJ-1/PARK7: Parkinson disease protein 7; \*p \< 0.05 vs. control group, Student's T-test. N = 5 in each group, every experiment was conducted in triplicate.](pone.0235849.g008){#pone.0235849.g008}

Discussion {#sec022}
==========

We successfully induced acute renal injury in mice via intraperitoneal injection of CDDP for 3 or 5 days. The levels of urinary creatinine, BUN and NAG were significantly elevated in the CDDP 3-day and CDDP 5-day groups compared to the control group (Figs [1](#pone.0235849.g001){ref-type="fig"} and [2](#pone.0235849.g002){ref-type="fig"}). Tubulointerstitial injury, such as tubular cell atrophy and cell infiltration \[[@pone.0235849.ref034], [@pone.0235849.ref035]\] were observed in the PAS-stained kidney sections of the mice treated with CDDP.

Development and progression of renal inflammation in response to CDDP is mediated via a complex network of inflammatory mediators. Among the numerous inflammatory cytokines, Volarevic *et al*. (2019) revealed that TNF-α is an important mediator of cisplatin-induced renal inflammation \[[@pone.0235849.ref005]\]. Moreover, CDDP-induced DNA damage upregulates TNF-α \[[@pone.0235849.ref006]\] and CDDP-induced AKI was attenuated in TNF-α-deficient mice or mice treated with TNF-α inhibitors or TNF-α neutralizing antibodies \[[@pone.0235849.ref036]\]. Renal parenchymal cells, macrophages and CD4^+^ T helper lymphocytes have been shown to secrete TNF-α in CDDP-induced AKI \[[@pone.0235849.ref007]\].

ROS and oxidative stress may trigger increased production of TNF-α. The TNF-α signaling pathways that culminate in activation of NF-κB are influenced by ROS and lead to upregulation of antioxidant proteins, demonstrating that TNF-α and ROS influence each other via a positive feedback loop \[[@pone.0235849.ref037]\]. We found the levels of TNF-α were significantly elevated in the CDDP 3-day group and CDDP 5-day group. Taken together, these results indicate that CDDP increases oxidative stress, which may trigger increased production of TNF-α. These results suggest that TNF-α may be an important regulator of oxidative stress in CDDP-induced AKI.

The balance between the levels of ROS and antioxidant enzymes plays a crucial role in CDDP-induced AKI \[[@pone.0235849.ref001], [@pone.0235849.ref002]\]. MG contains two carbonyl groups and generates advanced glycation end product adducts on proteins and nucleic acids, which lead to protein denaturation and malfunctions that can induce mitochondrial dysfunction and apoptosis \[[@pone.0235849.ref010]--[@pone.0235849.ref013]\]. In the present study, administration of CDDP for 3 and 5 days elevated the content of MG in the kidney ([Fig 4](#pone.0235849.g004){ref-type="fig"}). CDDP also tended to increase the levels of D-lactate ([Fig 5](#pone.0235849.g005){ref-type="fig"}), a metabolite of MG produced by the glyoxalase system \[[@pone.0235849.ref038]\]. Godbout *et al*. (2002) reported the presence of MG could enhance cisplatin-induced cytotoxicity: co-treatment of human myeloma cells with MG and cisplatin synergistically increased apoptosis (by 90% compared to the expected additive effect of MG and cisplatin) \[[@pone.0235849.ref039]\]. In addition, several studies have demonstrated MG may synergistically affect chemotherapy \[[@pone.0235849.ref040]--[@pone.0235849.ref042]\]. The levels of MG and its metabolite D-lactate correlated with oxidative stress and were associated with kidney injury in severe animal models \[[@pone.0235849.ref014], [@pone.0235849.ref019]--[@pone.0235849.ref021], [@pone.0235849.ref043]\]. Chou *et al*. (2015) demonstrated the levels of D-lactate correlated with the urinary albumin-to-creatinine ratio of diabetic nephropathy in humans \[[@pone.0235849.ref023]\]. In the present study, cisplatin increased the production of MG in the kidney, which was confirmed by the detection of elevated levels of the MG metabolite D-lactate. Moreover, the levels of MG and D-lactate were higher in mice administrated CDDP for 5 days than 3 days. Taken together, this study shows that MG may contribute to and represent an important pathological mechanism of CDDP-induced AKI.

We also conducted a proteomic study to identify proteins implicated in the association between MG and CDDP-induced nephrotoxicity. Two proteins were identified to be significantly associated with CDDP induced nephrotoxicity: SOD-1 and DJ-1. SOD-1 is a superoxide dismutase that localizes to the cytoplasm, peroxisomes and mitochondria. SOD-1 converts superoxide into hydrogen peroxide (H~2~O~2~), which is subsequently converted into water and oxygen by catalase or to water and oxidized glutathione by GSH-Px via consumption of glutathione disulfide \[[@pone.0235849.ref044]\]. Noori *et al*. (2010) demonstrated that CDDP-induced nephrotoxicity is related to oxidative stress, an unbalanced redox state, impairments to energy metabolism and increased apoptosis related to mitochondrial dysfunction in a rat model \[[@pone.0235849.ref045]\]. Our proteomic study and western blotting revealed that SOD-1 was significantly upregulated in the kidneys of the CDDP 3-day group (and tended to be higher in the CDDP 5-day group) than the control group. These results indicate CDDP increases the production of MG, which in turn leads to elevated oxidative stress. The increased expression of the ROS scavenging enzyme: SOD-1 in the kidneys of mice treated with CDDP may occur as a protective mechanism to compensate for increased oxidative stress \[[@pone.0235849.ref046]\].

The severe kidney damage in the CDDP 5-day group indicates the levels of oxidative stress exceeded the capacity of the tissues to compensate for oxidative stress, which would lead to a reduction in the levels of SOD-1. Moreover, high levels of protein denaturation and malfunctions induced by increased production of MG could also reduce the activity of anti-oxidative proteins in the kidneys of the CDDP 5-day group.

DJ-1 has been demonstrated to ameliorate oxidative stress by converting advanced glycation end products contributed by MG back to functional proteins and nucleotides \[[@pone.0235849.ref047]--[@pone.0235849.ref049]\]. Our proteomic study and western blotting showed the levels of DJ-1 were elevated in the CDDP 3-day group compared to the control group, indicating DJ-1 expression may increase as part of a mechanism to attenuate oxidative damage by converting advanced glycation end products back to functional proteins. However, in the CDDP 5-day group, the damage was beyond the self-repair capacity of the kidney and the cells had started to die, which in turn may decrease the expression of DJ-1. Interestingly, previous research reported the expression of c-Jun N-terminal kinases (JNKs) was mediated by TNF-α. The JNKs activate apoptosis, whereas DJ-1 inhibits apoptosis by inhibiting the expression of JNKs \[[@pone.0235849.ref050], [@pone.0235849.ref051]\]. Taken together, these results indicate DJ-1 may convert advanced glycation end products back to functional proteins and nucleotides to prevent cell death, and may also prevent apoptosis by inhibiting JNKs as a mechanism to protect against oxidative stress. The mechanism by which CDDP increases the production of MG was not investigated in this study. Chen *et al*. (2020) reported inflammatory reaction might enhance glycolysis, leading the content of MG increment, which is one of the by-products from glycolysis \[[@pone.0235849.ref052]\]. Späth *et al*. conducted CDDP induced AKI animal model and investigate the altered protein by LC-MS proteomic method and concluded that endogenous fatty acid biosynthesis is a key natural protective mechanism to counteracted CDDP nephrotoxicity \[[@pone.0235849.ref053]\]. Allaman *et al* reported despite glycolysis, lipid metabolism is an endogenous MG source as well \[[@pone.0235849.ref054]\]. Which could support the MG source in this animal model is mainly endogenous. The exact mechanism still needs further rigorous investigation.

There are several studies focused on CDDP induced kidney damage using proteomic analyzing method, tried to explore the pathological mechanism of CDDP nephrotoxicity and find potential marker. While the model nor the analyte are not consisting \[[@pone.0235849.ref053], [@pone.0235849.ref055]--[@pone.0235849.ref059]\]. This study used mice as experimental animal and liquid chromatography-tandem mass spectrometry (FD-LC-MS/MS) proteomic analysis method and found DJ-1 and SOD-1 were two proteins could support the role of MG in CDDP induced AKI, which may could provide as a foundation for novel treatment or prevention strategy.

Conclusions {#sec023}
===========

We successfully established a CDDP-induced mouse model of AKI. Our results indicate CDDP induces oxidative stress and upregulates MG in the kidney. MG increases oxidative stress and may play a crucial role in the pathology of CDDP-induced kidney damage. Similarly, CDDP also increased the production of the MG metabolite D-lactate. Our FD-LC-MS/MS proteomic study identified two antioxidant-related proteins, SOD-1 and DJ-1, were associated with CDDP-induced AKI. Based on our findings and the literature, we propose a mechanism for CDDP-induced AKI ([Fig 9](#pone.0235849.g009){ref-type="fig"}). The mechanism by which CDDP increases the production of MG was not investigated in this study and merits further investigation.

![Schematic illustration of the potential mechanism of cisplatin-induced acute kidney injury.\
CDDP induces oxidative stress and upregulates MG in the kidney. MG increases oxidative stress and upregulate SOD-1. Higher DJ-1expression level could increase the conversion of AGE contributed by MG back to functional proteins and nucleotides to prevent cell death, inflammation reaction and apoptosis.](pone.0235849.g009){#pone.0235849.g009}
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(PDF)

###### 

Click here for additional data file.

###### Differential proteins identified in the kidney tissues of the CDDP 3-day group vs. control mice.
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Dear Prof. Lee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

To consider  further the paper for publication, all the issue raised by the reviewers must be accurately addressed. In particular, appropriate controls should be included in figure 3 and the entire and coherent  western blot image should be  showed in figure 8.

We would appreciate receiving your revised manuscript by Jun 25 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Fabio Sallustio

Academic Editor
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1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for stating in the manuscript: \'All animal protocols followed the ethical guidelines of the Institutional Animal Care and Use Committee of Taipei Medical University (LAC-2019-0167).

a\. Please amend your current ethics statement to confirm that your named ethics committee specifically approved this study.

b\. Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE submissions requirements for ethics oversight of animal work, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-animal-research>

3\. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission's figures or Supporting Information files. This policy and the journal's other requirements for blot/gel reporting and figure preparation are described in detail at <https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements> and <https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files>. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: <https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels>.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at <plosone@plos.org> if you have any questions.
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Overall, this is an interesting manuscript. The rationale and literature review are appropriate. In general, the data support the conclusions reached by the authors. However, there are several points that need to be addressed by the authors. There are a couple of general comments followed by a more specific listing. First, in Figure 1-4 and 5-8, the text and figure caption mention that the comparisons are performed versus a control group. The figures mention a \"normal\" group. The labeling needs to be consistent with the text of the manuscript. I recommend changing the label on the figures to \'control\'. The other general comment has to do with Tables 1 and 2. Table 1 shows a 9.5 hour gradient for FD-HPLC and Table 2 show a 45 min gradient for proteomics analysis. Yet Figure 6, shows chromatograms for the protein separation and the text states \"FD-LC-MS/MS chromatograms\". Which gradient was used as the time scales are not consistent with the experimental section?

Specific comments:

1\. Page 5, line 7: \"PAGE\" needs to be defined.

2\. Page 7, lines 2-5: The authors should state that the additional MS and MASCOT details are provided later in the manuscript.

3\. Page 7, lies 10-12: What are the four animal groups? How many animals per group? need additional detail here.

4\. Page 15, line 19-20: What are the search criteria used?

5\. Page 19, Figure 1: What is \'n\' for each group? This information should be provided all the figures and in the figure captions.

6\. Page 26, Figure 4 caption: This caption is inadequate. Additional information in needed.

7\. Page 29, Figure 7: Again, the retention times of the identified proteins do not match the gradient given in Table 3.

After the authors have addressed these issues, the manuscript should be in a form suitable for publication.

Reviewer \#2: This paper by Chen et al. analyzes metabolites and proteins in cisplatin kidney injury model.

The following points deserve the authors' attention:

1\. The Figure 2 lacks scale bars and the different groups have different magnification. Not sure if anything can be concluded from them.

2\. The data in Figure 3 lacks positive and negative control and does not corroborate previous report son the role of TNFalpha in this model. The according literature is also not mentioned.

3\. The data in Figure 6 is not very clear and needs better representation with clear mass spectra, since derivates are depicted.

4\. The immunblot data in FIguer 8 does not represent the data shown in the quantification. Also MW markers should be added.

5\. Methods: From the methods section regarding the fluorescent derivatization, the experiments cannot be reproduced. It is not clear how proteins were identified since no tryptic digestion step is performed. If this was top down, more information on peptide/protein identification is needed. Like this, bioinformatic analysis is not feasible.

6\. Discussion:Very recent cisplatin proteomics studies have been performed. However, these studies are not mentioned and should be used to compare with the authors' proteomics findings. The following studies were not mentioned: PMID: 25450742, PMID: 30522767, PMID: 31493026, PMID: 31629959, PMID: 17021608PMID: 24265863

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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First of all, we appreciated both reviewers to point out the blind points that we did not notice or should state more clearly in the beginning. Here are our responses for the specific comments by each reviewer.

Response to general comment by reviewer 1:

We appreciate for you kindly remind us the writing mistake. Figure captions had been revised according to your suggestion.

To response the question by regarding to the retention time of protein separation chromatograms (figure 6). Table 1 shows a 570 min gradient for the HPLC protein separation of mice kidney homogenate. Then, the separated sample were analyzed by LC-MS/MS, which using a 45 mins gradient which shows in Table 2. Figure 6. indicate the result of HPLC protein separation, which the scale does correspond with the 570 min gradient program. The retention time in Table 3 is the MSSCOT database comparison results and the peak height in Figure 7 indicate the protein expression in each group. Here we would like to apologize for the low resolution of the picture of chromatogram due to the software issue. We had tried our best to improve the quality of the pictures.

Response to specific comment 1: The abbreviation had been changed into "Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE)".

Response to specific comment 2: The MASCOT research detail had been added into the revised draft, please see the attached file \"Response to reviewers\".

Response to specific comment 3:The sections describe animal grouping had been revised, please see the attached file \"Response to reviewers\".

Response to specific comment 4: The MASCOT research detail had been added into the revised draft, please see the attached file \"Response to reviewers\".

Response to specific comment 5: The figure captions had been revised, please see the attached file \"Response to reviewers\".

Response to specific comment 6: The figure caption had been revised, please see the attached file \"Response to reviewers\".

Response to specific comment 7: Regarding to the retention time of chromatograms. Our answer is in the response to general comments. In brief, Table 1 shows a 570 min gradient program and Figure 6. indicate the result of HPLC protein separation. The retention time in Table 3 is the MSSCOT database comparison results and the peak height in Figure 7 indicate the protein expression in each group.

Response to comments by reviewer 2:

Response to comment 1: To add the scale bar to Figure 2, we had obtained a new set of histological sections' pictures, and rescored the section. The result consists with pervious scoring result. Scale bar had added to the revised figure.

Response to comment 2:

a\) Regarding to the positive or negative control in the immunofluorescence image, we do recognize the importance of the controls, which could provide a clearer and solid evidence to enhance the causality. In this research, immunofluorescence analysis was conducted on the section of mice kidney samples, the negative control could achieve by using TNF-α gene knock-out mice. Considering the weight of benefit using gene mice and to reduce using experimental animals, we did not include negative control into our experiment design. Furthermore, in our previous published article, the immunofluorescence analysis conducted in mice kidney sections did not include negative control, neither (PMID: 31968011). Therefore, we believe without negative control could still represent the result correctly.

b\) Our immunofluorescence analysis result of TNF-α revealed the level of TNF-α was correlated with the kidney damage by observing the biomedical analysis and histological images. ROS attributed by methylglyoxal is a key concept in our study (Figure 9). We believed CDDP could increase the level of methylglyoxal and elevate ROS, which trigger the increased production of TNF-α.

Response to comment 3: As the response to Reviewer \#1, we apologize for the low resolution of chromatogram due to the software issue. We had tried our best to improve the quality of the pictures and the figure had been revised to improve resolution.

Response to comment 4: To add the molecule weight marker to the western blot image, we re-conducted gel electrophoresis and semi-quantification. The trend consisted with the previous results. The images had been revised.

Response to comment 5: Our protein separation method included trypsin digestion step. After the separation by HPLC, 2.5 μL of 10 mM CaCl2, 20 μL of 50 mM NH4CO3 and 2.5 μL trypsin were added to the protein residues and incubated at 37 °C for 2 h for the digestion. And this protein identification method had been published in several articles (PMID: 31968011, PMID: 19714884, PMID: 29088495, PMID: 22972526), we have confidence that this method is dependable. And the detail MASCOT research had been revised, please see the attached file \"Response to reviewers\".

Response to comment 6: Here, we are grateful for the reviewer raising the point that we did not attention previously. After we read the references that Reviewer \#2 provided, the discussion in the main draft was revised as below, and references provided by the reviewer had been cited. The discussion in main draft had been revised, please see the attached file \"Response to reviewers\".
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Submitted filename: Response to reviewers.docx
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Click here for additional data file.
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Dear Dr. Lee,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the minor points raised during the review process.

Please submit your revised manuscript by Aug 03 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Fabio Sallustio

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors do an adequate job of addressing previous reviewer concerns. However, there are several minor points/wording issues that the authors should address. These points are listed below in order of appearance in the manuscript.

1\. Page 7, lines 13-14: The sentence should be written as: \"Five animals were allocated into each group.\"

2\. Page 16, lines 1-5: The paragraph need to be rewritten. Suggestion \"After detection, data was submitted to MASCOT, a protein identification program \.... MASOCT is widely-used protein identification search engine. Line 5: the word \"collate\" should be deleted.

Figure captions 1, 2, 3, 4, 5 and 8: The words \"triple repeat\" should be deleted and replaced with \'in triplicate\'

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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This letter is to response to the issues raised by Reviewer in minor revision.

Again, we are appreciated to Reviewer's kindly remind us the writing and grammarly mistakes. We had amended the paragraph according to the Reviewer's suggestion. The following is the response to the comments from Reviewer.

Comment 1: Page 7, lines 13-14: The sentence should be written as: \"Five animals were allocated into each group.\"

Response: The paragraph had been revised, please see the attached file \"Response to reviewer\".

Comment 2: Page 16, lines 1-5: The paragraph need to be rewritten. Suggestion \"After detection, data was submitted to MASCOT, a protein identification program \.... MASOCT is widely-used protein identification search engine. Line 5: the word \"collate\" should be deleted.

Response: The paragraph had been revised, please see the attached file \"Response to reviewer\".

Comment 3: Figure captions 1, 2, 3, 4, 5 and 8: The words \"triple repeat\" should be deleted and replaced with \'in triplicate\'

Response: The figure caption had been revised, please see the attached file \"Response to reviewer\".
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Dear Dr. Lee,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.
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